Common CX3CR1 alleles are associated with a reduced risk of headaches
Christophe Combadière1, Ophelia Godin, Cécile Vidal
1INSERM U543, Laboratoire d'Immunologie Cellulaire, Faculté de Médecine Pitié-Salpêtrière, 91 Boulevard de l'Hôpital, 75634 Paris, France.
Objectives:
The aim of this study was to investigate the role of the chemokine receptor CX3CR1 in headaches and migraine.
Methods:
Distribution of 2 polymorphisms of the chemokine receptor CX3CR1 (V249I and T280M) was determined in a population-based sample of 1179 elderly individuals.
Results:
Heterozygotes for both CX3CR1 polymorphisms had a reduced risk of recurrent headaches, with an odds ratio (OR) of 0.64 (95% confidence interval [CI] = 0.46-0.90) for the I249 allele and 0.55 (95% CI = 0.38-0.81) for the M280 allele. Haplotype analysis showed that carriers of the rarer CX3CR1 I249-M280 haplotype had a reduced risk of recurrent headaches, with an OR of 0.57 (95% CI = 0.41-0.80, P = .001). This association was seen for both nonmigraine headaches (OR = 0.47, 95% CI = 0.28-0.79, P = .004) and migraine (OR = 0.65, 95% CI = 0.43-0.98, P = .041).
Conclusions:
These results need to be replicated but suggest that the chemokine receptor CX3CR1 may play a role in recurrent headaches.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic Lingo
X-linked Traits
Pharmacogenomics: Identification of New Drug Targets
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
